Table 1 Baseline variables and micropaticles in OR group and PD group of 86 cases of NSCLC
Variables | OR (n = 60) | PD (n = 26) | P |
|---|---|---|---|
Male, gender, n(%) | 45 (75.0) | 19 (73.1) | 0.851* |
Age, years, x ± s | 61.8 ± 10.7 | 62.6 ± 11.1 | 0.760§ |
Current or former smokers, n(%) | 31 (51.7) | 17 (65.4) | 0.239* |
Histology, n(%) | Â | Â | 0.297* |
 Adenocarcinoma | 25 (41.7) | 14 (53.8) |  |
 Squamous carcinoma | 35 (58.3) | 12 (46.2) |  |
Disease stage, n(%) | Â | Â | 0.274* |
 Stage III | 26 (43.3) | 8 (30.8) |  |
 Stage IV | 34 (56.7) | 18 (69.2) |  |
Lines of therapy, n (%) | Â | Â | 0.759* |
 <2 | 21 (35.0) | 10 (38.5) |  |
  ≥ 2 | 39 (65.0) | 16 (61.5) |  |
Therapeutic intervention, n(%) | Â | Â | 0.343* |
 Chemotherapy+Immunotherapy | 31 (51.7) | 10 (38.5) |  |
 Chemotherapy | 21 (35.0) | 9 (34.6) |  |
 Immunotherapy | 5 (8.3) | 3 (11.5) |  |
 Target therapy | 3 (5.0) | 4 (15.4) |  |
No. of metastatic organs, n(%) | Â | Â | 1.000* |
 <2 | 30 (50.0) | 13 (50.0) |  |
  ≥ 2 | 30 (50.0) | 13 (50.0) |  |
No. of metastatic lymph nodes, n(%) | Â | Â | 0.773* |
 <2 | 18 (30.0) | 7 (26.9) |  |
  ≥ 2 | 42 (70.0) | 19 (73.1) |  |
KPS score, n(%) | Â | Â | 0.733* |
 90 | 54 (90.0) | 22 (84.6) |  |
 80 | 4 (6.7) | 2 (7.7) |  |
 70 | 2 (3.3) | 2 (7.7) |  |
Laboratory indices at baseline, median(IQR) | Â | Â | Â |
 Neutrophils, ×109/L | 3.61 [2.70,4.50] | 3.62 [2.87,4.63] | 0.929# |
 Platelets, ×109/L | 205 [154,258] | 200 [144,265] | 0.914# |
 NLR | 3.32 [2.11,4.60] | 3.27 [1.75,4.56] | 0.803# |
 LDH, U/L | 191 [160,229] | 188 [164,237] | 0.566# |
 CEA, ng/ml | 5.10 [1.94,32.71] | 5.23 [1.81,36.86] | 0.925# |
 CYFRA 21-1, ng/ml | 5.14 [3.33,7.93] | 5.50 [3.33,8.98] | 0.413# |
 SCC, ng/ml | 1.10 [0.85,1.63] | 1.08 [0.82,1.75] | 0.745# |
Micropaticals at baseline, events/μL, median(IQR) |  |  |  |
 total MPs | 2632 [1942,3600] | 2586 [1311,3490] | 0.771# |
 NMPs | 164 [118,317] | 217 [121,267] | 0.836# |
 PMPs | 205 [154,258] | 174 [143,211] | 0.951# |